The Indian government is considering the Russian government’s request to conduct phase 3 trials of the covid Sputnik V vaccine in the country and also to manufacture the vaccine in the country, said Dr. VK Paul, member (health) of NITI Aayog.
The Indian government of India attaches great importance to this partnership offer from a very special friend of this nation, and there has been significant movement in both tracks, he said.
Dr. Paul heads the National Group of Experts on Vaccine Administration for COVID-19.
In August, Russia had registered its first candidate vaccine, developed by the Gamaleya Institute in Moscow, after completing the first human trials.
The Sputnik V vaccine is currently in phase 3 trials in Russia. The Sputnik V vaccine produced an antibody response in all participants in the early-stage trials, according to results published last week in The Lancet medical journal.
The Sputnik-V vaccine is given in two doses, each based on a different vector that normally causes the common cold: the human adenoviruses Ad5 and Ad26.
Russian Health Minister Mikhail Murashko has said that Russia will begin mass inoculation from November or December, with a focus on high-risk groups.
More than half a dozen drug manufacturers are already conducting advanced clinical trials, each with tens of thousands of participants.
In India, clinical trials are currently underway with three vaccines, including the Oxford vaccine. (With ANI inputs)
.
